Circio Holding ASA Approval and publication of prospectus for potential future share issues and conversion of convertible bonds

The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today approved a securities note, a registration document and a summary (together referred to as the "Prospectus"), which prepares for potential future share issues and conversions of bonds under the bond terms and the Investment Agreement with Atlas Special Opportunities LLC and Atlas Capital Markets LLC. The Prospectus is available on the Company's website: https://www.circio.com/en/section/investors/prospectus/ (https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.circio.com%2Fen%2Fsection%2Finvestors%2Fprospectus%2F&data=05%7C02%7Cmats.hermansen%40circio.com%7C5b2e58c7684c4d70a6ac08ddfb51ad30%7C66b0661a3ec348a8a9665b0cce82b3fe%7C0%7C0%7C638943050431341713%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=9SJuyOMF64W0LRHXWdxnIB0L95IPhXj3qSImT75gnGo%3D&reserved=0)

For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com

Lubor Gaal, CFO Phone: +34 683 34 3811 Email: lubor.gaal@circio.com

About Circio Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology program, TG01, through cost-efficient external academic and industry collaborations. TG01 targets RAS-mutated cancers and is being tested in two clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine adjuvanted by STIMULON QS-21 licensed from Agenus Inc.